Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT + cadonilimab (AK104) with platinum-etoposide as first-line therapy for extensive-stage SCLC
ChiCTR2600124606Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in small cell lung cancer (SCLC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety and 6-month progression-free survival rate. Started May 2026; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600124606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124606.